CYP51C Y319H and H349R substitutions cannot confer azole resistance in Aspergillus flavus NRRL 3357-5
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.00425-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Ya Bin Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Aspergillus flavus, Antifungal Agents, Drug Resistance, Fungal, Azoles. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
Azole antifungals inhibit the cytochrome P450-dependent lanosterol 14-α-demethylase (CYP51), an essential enzyme in the ergosterol biosynthetic pathway. While azole resistance mechanisms are well established in Aspergillus fumigatus , the molecular basis of resistance in Aspergillus flavus remains less defined. Previous studies identified nonsynonymous substitutions Y319H and H349R in CYP51C of azole-resistant A. flavus isolates, but their functional significance had not been experimentally confirmed. In this study, we used targeted gene replacement to introduce these mutations individually into a wild-type A. flavus background and assessed their impact on azole susceptibility and fitness. Sequence alignment revealed that residues Y319 and H349 are not conserved among fungal CYP51 (synonym “ERG11”) homologs. Both mutant strains exhibited the same susceptibility profiles to itraconazole, voriconazole, posaconazole, isavuconazole, echinocandins, and amphotericin B as the wild-type control. Moreover, colony growth and sporulation were comparable across all strains, indicating no measurable fitness cost associated with either substitution. These results indicate that CYP51C Y319H and H349R may not confer azole resistance or affect fungal fitness, underscoring the necessity of functional validation to distinguish neutral polymorphisms from true resistance determinants in A. flavus . IMPORTANCE Azole resistance in Aspergillus flavus is an emerging clinical concern, yet its molecular basis remains poorly defined. This study demonstrates that two previously reported CYP51C substitutions (Y319H and H349R) do not confer azole resistance or affect fungal fitness when tested experimentally. Our findings highlight that the presence of mutations in resistant isolates does not necessarily imply causality. By emphasizing the need for functional validation, this work helps prevent misinterpretation of neutral polymorphisms as resistance markers and improves the accuracy of molecular diagnostics and resistance surveillance in A. flavus .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Peking University Third Hospital, Beijing, China.
- Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
ORCID-Profile: Ya Bin Zhou, Jos Houbraken
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
Zitieren
APA
Zhou, Y. B., Grum-Grzhimaylo, A. A., Meijer, M., Kraak, B., & Houbraken, J. (2026). CYP51C Y319H and H349R substitutions cannot confer azole resistance in Aspergillus flavus NRRL 3357-5. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00425-26
Vancouver
Zhou YB, Grum-Grzhimaylo AA, Meijer M, Kraak B, Houbraken J. CYP51C Y319H and H349R substitutions cannot confer azole resistance in Aspergillus flavus NRRL 3357-5. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00425-26
BibTeX
@article{Zhou2026,
author = {Zhou, Ya Bin and Grum-Grzhimaylo, Alexey A and Meijer, Martin and Kraak, Bart and Houbraken, Jos},
title = {CYP51C Y319H and H349R substitutions cannot confer azole resistance in Aspergillus flavus NRRL 3357-5},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.00425-26}
}
EUVIMED